# PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

> **NCT01000025** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 720 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** PF-00299804
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01000025
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-23
- **Primary completion:** 2014-01-15
- **Final completion:** 2015-11-27
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000025, "PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01000025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*